CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
SHR-1918drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06009393
NCT06009393Phase 2Completed
CompareCT.gov

A Single-Arm, Open-Label, Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Beijing Suncadia Pharmaceuticals Co., Ltd·interventional·Posted Aug 24, 2023·Updated Sep 5, 2025

In Brief

A Phase 2 clinical trial evaluating SHR-1918 for Homozygous Familial Hypercholesterolemia. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This is a single-arm, open-label study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with homozygous familial hypercholesterolemia (HoFH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHomozygous Familial Hypercholesterolemia
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedAug 24, 2023
Enrollment StartDec 22, 2023
Primary CompletionJun 29, 2024
Study CompletionAug 23, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.9 years ago

Interventions

SHR-1918drug

Three administration